Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
266
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
-8.07M
-
Total reported value, excl. options
-
$2.77B
-
Value change
-
-$155M
-
Put/Call ratio
-
0.19
-
Number of buys
-
147
-
Number of sells
-
-119
-
Price
-
$22.63
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q3 2025
334 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q3 2025.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 266 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 128M outstanding shares and own 95.88% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (12.2M shares), VANGUARD GROUP INC (9.99M shares), MORGAN STANLEY (9.64M shares), WELLINGTON MANAGEMENT GROUP LLP (9.29M shares), Deep Track Capital, LP (8M shares), BlackRock, Inc. (6.27M shares), AQR CAPITAL MANAGEMENT LLC (4.49M shares), JENNISON ASSOCIATES LLC (4.35M shares), STATE STREET CORP (4.04M shares), and EcoR1 Capital, LLC (3.45M shares).
This table shows the top 266 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.